Alembic Pharmaceuticals Ltd

Alembic Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Pharmaceuticals Ltd

₹ 762 0.87%
25 May - close price
alembic-india.com BSE: 533573 NSE: APLLTD
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company
The company is a leading research-driven, integrated pharmaceutical company specializing in generic formulations across diverse platforms. [1]

Website BSE NSE
  • Market Cap ₹ 14,989 Cr.
  • Current Price ₹ 762
  • High / Low ₹ 1,108 / 635
  • Stock P/E 21.6
  • Book Value ₹ 286
  • Dividend Yield 1.44 %
  • ROCE 12.2 %
  • ROE 12.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 37.4%

Cons

  • Stock is trading at 2.67 times its book value
  • The company has delivered a poor sales growth of 5.59% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 12.2% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,307 1,332 1,479 1,588 1,475 1,476 1,580 1,406 1,571 1,494 1,796 1,642 1,719
1,138 1,167 1,271 1,251 1,186 1,184 1,321 1,226 1,400 1,280 1,493 1,371 1,445
Operating Profit 169 166 207 337 288 291 259 180 171 214 303 272 274
OPM % 13% 12% 14% 21% 20% 20% 16% 13% 11% 14% 17% 17% 16%
2 12 9 3 7 3 29 15 13 8 11 -32 1
Interest 14 14 15 15 10 13 18 22 24 23 23 22 19
Depreciation 74 66 67 69 69 69 70 70 69 73 76 80 82
Profit before tax 84 98 134 257 216 213 200 104 92 126 216 139 173
Tax % -55% 0% 0% 9% 7% 17% 17% 17% 18% 18% 17% 18% -40%
131 98 134 233 202 176 166 86 75 104 179 114 243
EPS in Rs 6.64 4.96 6.81 11.87 10.27 8.96 8.43 4.37 3.83 5.27 9.12 5.82 12.37
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,019 3,009 2,986 2,945 3,660 4,133 5,067 5,035 5,149 5,874 6,033 6,651
1,611 2,026 2,353 2,313 2,782 2,930 3,618 4,127 4,484 4,875 5,131 5,589
Operating Profit 408 983 633 633 879 1,203 1,449 909 665 999 901 1,063
OPM % 20% 33% 21% 21% 24% 29% 29% 18% 13% 17% 15% 16%
3 7 3 7 6 125 84 51 3 31 61 -11
Interest 3 4 3 2 15 25 13 17 49 54 76 87
Depreciation 44 72 83 102 106 136 183 285 273 271 277 311
Profit before tax 363 914 550 535 765 1,167 1,338 658 346 704 609 654
Tax % 21% 24% 22% 21% 20% 17% 18% 17% -0% 5% 17% 2%
287 699 431 422 611 969 1,097 544 347 666 503 640
EPS in Rs 15.20 37.06 22.84 22.38 32.42 51.42 55.79 27.65 17.64 33.91 25.60 32.58
Dividend Payout % 23% 11% 18% 18% 17% 19% 25% 36% 45% 32% 43% 37%
Compounded Sales Growth
10 Years: 8%
5 Years: 6%
3 Years: 9%
TTM: 10%
Compounded Profit Growth
10 Years: 0%
5 Years: -9%
3 Years: 26%
TTM: 42%
Stock Price CAGR
10 Years: 3%
5 Years: -4%
3 Years: 12%
1 Year: -22%
Return on Equity
10 Years: 16%
5 Years: 11%
3 Years: 12%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 38 38 38 38 38 38 39 39 39 39 39 39
Reserves 796 1,493 1,830 2,157 2,675 3,308 5,062 5,251 4,375 4,870 5,155 5,576
194 0 8 622 1,059 1,687 584 706 710 492 1,194 1,198
484 651 634 862 777 846 958 1,078 1,006 998 1,168 1,338
Total Liabilities 1,511 2,182 2,509 3,678 4,549 5,879 6,643 7,074 6,130 6,399 7,556 8,151
489 697 799 918 1,085 1,276 1,774 1,771 2,377 2,536 2,513 2,878
CWIP 83 92 348 741 1,107 1,570 2,183 2,304 601 524 837 634
Investments 33 37 103 299 506 833 343 219 229 227 260 271
906 1,355 1,259 1,720 1,850 2,199 2,344 2,779 2,922 3,112 3,946 4,368
Total Assets 1,511 2,182 2,509 3,678 4,549 5,879 6,643 7,074 6,130 6,399 7,556 8,151

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
180 848 327 305 809 540 1,485 545 730 773 227 809
-199 -292 -511 -794 -754 -822 -926 -369 -461 -329 -636 -483
18 -276 -96 498 80 166 -534 -217 -261 -445 404 -318
Net Cash Flow -1 280 -280 9 135 -116 25 -40 8 -2 -6 8
Free Cash Flow -21 558 -119 -290 244 -88 884 124 287 448 -327 376
CFO/OP 61% 106% 70% 68% 110% 61% 119% 74% 118% 78% 30% 84%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 61 45 57 77 54 69 30 72 85 83 90 88
Inventory Days 195 240 237 274 325 375 376 339 280 274 403 370
Days Payable 162 225 177 246 173 137 148 139 131 126 148 119
Cash Conversion Cycle 95 60 117 105 207 307 258 272 234 232 345 339
Working Capital Days 42 57 82 94 44 58 80 83 85 102 94 90
ROCE % 41% 72% 32% 23% 24% 27% 25% 12% 7% 14% 11% 12%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Cumulative ANDA approvals (Final + Tentative)
Number

Log in to view insights

Please log in to see hidden values.

Login
Cumulative ANDA filings
Number
Cumulative US DMF Filings
Number
Number of Manufacturing Facilities
Number
R&D Spend as % of Sales
%
Number of Scientists / R&D Personnel
Number
Field Force Strength (Medical Representatives)
Number
India Branded Business Market Share (IPM)
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.67% 69.68% 69.74% 69.74% 69.74%
4.34% 4.51% 4.52% 4.46% 4.32% 3.94% 4.17% 3.94% 3.96% 4.04% 4.23% 4.26%
13.65% 14.22% 14.51% 15.39% 15.47% 16.05% 16.05% 16.43% 16.46% 16.30% 16.17% 16.17%
12.39% 11.67% 11.36% 10.54% 10.61% 10.38% 10.17% 9.96% 9.91% 9.92% 9.84% 9.83%
No. of Shareholders 97,60789,55285,21276,56774,82991,42993,94491,33689,01389,96987,00086,432

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls